The Form 144 is an advance notice of intent to sell; the actual sale may or may not occur. Given Goldsmith's history of routine RSU-based sales, this filing carries no material signal. Monitor for a subsequent Form 4 to confirm execution. No change to investment thesis.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $156.58entry
- T+1 · 5mo ago +0.76%α +2.01% · $157.77
- T+5 · 5mo ago +8.26%α +10.49% · $169.51
- T+20 · 4mo ago +18.13%α +17.93% · $184.97
- T+60 · 2mo ago +29.87%α +28.87% · $203.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director and Officer Mark A. Goldsmith filed a Form 144 indicating intent to sell 9,772 shares of Revolution Medicines common stock, valued at approximately $1.5M based on the filing date price. The shares were acquired via restricted stock unit grants in 2023-2025. This is a routine sale consistent with Goldsmith's prior selling pattern (132,871 shares sold in the past three months) and does not signal a change in company outlook.
Key Facts
- Mark A. Goldsmith (Officer/Director) filed Form 144 to sell 9,772 shares of RVMD common stock.
- Estimated value of proposed sale: ~$1,503,617.64 (based on ~$153.86/share).
- Shares to be sold were acquired from RSU grants on 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,266 shares).
- Goldsmith sold 12,871 shares on 03/17/2026 and 120,000 shares on 04/15/2026, totaling 132,871 shares in the prior three months.
- Company market cap is ~$32.7B; analyst consensus is 96% bullish (26 analysts: 11 Strong Buy, 15 Buy).
Financial Impact
Not specified
Risk Factors
- Insider selling could be misinterpreted as negative signal by the market, though the pattern is routine.
- Additional unannounced sales by other insiders could accumulate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001246842-26-000002 |
| Document: 0001246842-26-000002-index.html | 0001246842-26-000002 |
| Document: 0001246842-26-000002.txt | 0001246842-26-000002 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers